{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Number of patients who developed acute/chronic GVHD post-transplant. aGVHD Stages\n\nSkin:\n\na maculopapular eruption involving \\< 25% BSA a maculopapular eruption involving 25 - 50% BSA generalized erythroderma generalized erythroderma with bullous formation and often with desquamation\n\nLiver:\n\nbilirubin 2.0 - 3.0 mg/100 mL bilirubin 3 - 5.9 mg/100 mL bilirubin 6 - 14.9 mg/100 mL bilirubin \\> 15 mg/100 mL\n\nGut:\n\nDiarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients with visible bloody diarrhea are at least stage 2 gut and grade 3 overall.\n\naGVHD Grades Grade II: Stage 1 - 3 skin and/or stage 1 gut involvement and/or stage 1 liver involvement Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death","groups":[{"description":"Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo radiotherapy\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Arm I (Nonmyeloablative Conditioning With Fludarabine and TBI)"},{"description":"Patients undergo TBI on day 0. All patients then undergo allogeneic peripheral blood stem cell transplantation on day 0 and receive tacrolimus PO every 12 hours on days -3 to 180, with taper on day 56, or tacrolimus IV if unable to tolerate PO; and mycophenolate mofetil PO every 12 hours on days 0-27 or mycophenolate mofetil IV if unable to tolerate PO.\n\ntotal-body irradiation: Undergo radiotherapy\n\nmycophenolate mofetil: Given IV or PO\n\ntacrolimus: Given IV or PO\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplant\n\nnonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplant\n\nlaboratory biomarker analysis: Correlative studies","id":"OG001","title":"Arm II (Nonmyeloablative Conditioning With TBI)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 180 post-transplantation","title":"Incidences of Grades II-IV Acute GVHD","type":"SECONDARY","unitOfMeasure":"Participants"}